Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
The New England Journal of Medicine|December 14, 2016
Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11BDivya Punwani, Yong Zhang, Jason Yu, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 9, 2024
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II TrialMatthew Matasar, Nancy L Bartlett, Mazyar Shadman, et al.
The Journal of Allergy and Clinical Immunology|July 2, 2013
Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 yearsAntonia Kwan, Joseph A Church, Morton J Cowan, et al.
Clinical Pharmacology and Therapeutics|September 27, 2024
A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular LymphomaChi-Chung Li, Brendan Bender, Justin Wilkins, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 21, 2020
Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancerZia Khan, Flavia Di Nucci, Antonia Kwan, et al.
Clinical and Translational Science|April 25, 2025
Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular LymphomaJunyi Li, Michael Z Liao, Justin Wilkins, et al.
Blood Advances|February 5, 2026
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformationKatharine Louise Lewis, Sarit E Assouline, Ross Ian Baker, et al.
The Lancet. Oncology|July 8, 2022
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 studyLihua E Budde, Laurie H Sehn, Matthew Matasar, et al.
Blood|October 24, 2024
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapiesLaurie H Sehn, Nancy L Bartlett, Matthew J Matasar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2024
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II StudyLihua E Budde, Sarit Assouline, Laurie H Sehn, et al.
Pageof 3